Quest Diagnostics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
Quest Diagnostics şirketinin kazançları yıllık ortalama -20.3% oranında azalırken, Healthcare sektörünün kazançları yıllık 9.9% oranında artan oldu. Gelirler yıllık ortalama 0.3% oranında azalan oldu. Quest Diagnostics şirketinin öz sermaye getirisi 13.9% olup, net marjı 9% dir.
Anahtar bilgiler
-20.28%
Kazanç büyüme oranı
-16.08%
EPS büyüme oranı
| Healthcare Sektör Büyümesi | 8.50% |
| Gelir büyüme oranı | -0.32% |
| Özkaynak getirisi | 13.88% |
| Net Marj | 9.04% |
| Son Kazanç Güncellemesi | 31 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely
Apr 24
DGX: Organic Guidance And Capital Returns Will Sustain Safe Haven Appeal
Analyst price targets for Quest Diagnostics have been adjusted slightly lower to $218.19 from $218.50, as analysts factor in updated views on revenue growth, profit margins, and long term P/E assumptions following a series of recent target changes across the coverage universe. Analyst Commentary Recent research updates point to a mixed but generally constructive stance on Quest Diagnostics, with multiple target changes and one fresh list inclusion helping to frame how analysts are thinking about valuation, execution, and growth risk.DGX: Organic Guidance And Capital Returns Will Support Safe Haven Profile
Analysts have raised their price targets on Quest Diagnostics by between $5 and $30, largely pointing to recently issued organic revenue growth guidance and viewing the broader diagnostic lab space as a relative safe haven within healthcare services. Analyst Commentary Recent Street research around Quest Diagnostics and its closest peer highlights a constructive setup for the broader diagnostic lab group, with price target moves on Quest generally framed against views that the sector can act as a relative safe haven within healthcare services.DGX: Premium Multiple And Capital Returns Look Supported By Organic Revenue Guidance
Analysts have raised their price targets on Quest Diagnostics by a range of $5 to $30, citing the company’s recent organic revenue growth guidance and viewing the diagnostic testing space as a relative safe haven within healthcare services. Analyst Commentary Recent research on Quest Diagnostics highlights a cluster of higher price targets and an upgrade, with many investors treating large diagnostic labs as a relatively defensive corner of healthcare services.DGX: Fair Outlook As Premium Multiple And Capital Returns Shape Future Earnings
Analysts raised their price target on Quest Diagnostics by about $1 to $218.50, reflecting refined assumptions that include slightly higher revenue growth, a similar discount rate, modestly adjusted profit margins, and a small change in future P/E expectations, supported by broadly positive recent research across the diagnostic lab space. Analyst Commentary Street research around Quest Diagnostics has focused on how the company is positioned within the broader diagnostic lab group, with recent moves in peer guidance and a series of price target changes shaping sentiment on both upside potential and execution risk.DGX: Fair Outlook As Higher Payouts And Consumer Labs Support Future Earnings
Analysts have lifted their price target on Quest Diagnostics by about $18, reflecting slightly higher modeled revenue growth and a somewhat richer future P/E assumption, even as projected profit margins are trimmed in line with recent Street research that has broadly raised targets across the lab testing group. Analyst Commentary Bullish analysts have broadly raised their price targets on Quest Diagnostics, reflecting a more constructive view on the lab testing group as a whole and on Quest's positioning within it.DGX: Fair Outlook As Consumer Lab Partnerships And Margins Support Future Earnings
Analysts have inched up their fair value estimate for Quest Diagnostics to about $199 per share, a move they tie to slightly higher margin and P/E assumptions following recent research that points to potential upside to current earnings estimates. Analyst Commentary Recent Street research points to potential upside to current earnings estimates for Quest Diagnostics, which is feeding into a more constructive view on the stock’s valuation and execution risk.DGX: Future Consumer Lab Partnerships And Neurology Tests Will Support Balanced Outlook
Analysts have inched up their price target on Quest Diagnostics to about $198.38 from roughly $198.06, reflecting refreshed assumptions around slightly higher revenue growth, a small adjustment to profit margins, and a near steady forward P/E outlook. What's in the News Hims & Hers Health is offering lab testing that it views as a potential US$1b business, with customers accessing testing through Quest Diagnostics and then receiving results and care plans through the Hims platform (Wall Street Journal).DGX: Future Lab Partnerships And Testing Pipeline Will Support Bullish Outlook
Analysts lifted their price target for Quest Diagnostics by about US$1 to roughly US$198, citing recent Q3 results with sales and earnings ahead of consensus; raised full year guidance; firm organic volume trends; and growing interest in longer term opportunities, such as the Haystack MRD test and a generally supportive lab testing backdrop. Analyst Commentary Street research following the Q3 report points to a generally constructive tone, with multiple firms lifting their price targets and highlighting both execution on current fundamentals and potential longer term growth drivers.DGX: Future Lab Partnerships And Testing Pipeline Will Support Balanced Outlook
Analysts have nudged their price targets on Quest Diagnostics higher by between $5 and $25 per share, citing solid Q3 outperformance, raised guidance, and confidence in organic growth and future testing catalysts. Analyst Commentary Street research following the Q3 print highlights a generally constructive stance on Quest Diagnostics, with most price target increases framed around stronger than expected fundamentals and improving visibility into growth drivers over the next two years.DGX: Future Volume Gains And Lab Partnerships Will Support Balanced Outlook
The analyst price target for Quest Diagnostics was modestly increased to $197.31 from $197.25. Analysts cited stronger-than-expected earnings, raised guidance, and continued positive core trends as the rationale for the update.DGX: Future Revenue Expansion And Partnerships Will Balance Near-Term Risks
Quest Diagnostics saw its analyst price target increase, with several firms now projecting new targets between $195 and $215 per share. Analysts cite strong quarterly results and ongoing positive momentum in core business trends.DGX: Core Volume Momentum And New Blood Tests Will Drive Share Momentum
Quest Diagnostics' analyst fair value estimate has been raised from $191.56 to $197.25 per share. This change reflects analysts' upbeat outlook after strong quarterly results, improved profit margins, and continued momentum in core business trends.Preventive Diagnostics And Automation Will Shape Future Healthcare
Analysts have raised their fair value estimate for Quest Diagnostics from $188.19 to $191.56 per share, citing ongoing stable end markets and improving revenue growth expectations. Analyst Commentary Recent street research has highlighted a mix of optimism and caution surrounding Quest Diagnostics.Earnings Not Telling The Story For Quest Diagnostics Incorporated (NYSE:DGX)
Aug 20
Return Trends At Quest Diagnostics (NYSE:DGX) Aren't Appealing
Jun 21Is Quest Diagnostics Incorporated (NYSE:DGX) Trading At A 48% Discount?
May 11Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation
Jan 28Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Quest Diagnostics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 11,278 | 1,020 | 1,955 | 0 |
| 31 Dec 25 | 11,035 | 988 | 1,920 | 0 |
| 30 Sep 25 | 10,850 | 963 | 1,891 | 0 |
| 30 Jun 25 | 10,522 | 945 | 1,832 | 0 |
| 31 Mar 25 | 10,158 | 892 | 1,758 | 0 |
| 31 Dec 24 | 9,872 | 866 | 1,731 | 0 |
| 30 Sep 24 | 9,539 | 838 | 1,681 | 0 |
| 30 Jun 24 | 9,346 | 836 | 1,624 | 0 |
| 31 Mar 24 | 9,287 | 842 | 1,621 | 0 |
| 31 Dec 23 | 9,252 | 850 | 1,630 | 0 |
| 30 Sep 23 | 9,297 | 759 | 1,748 | 0 |
| 30 Jun 23 | 9,488 | 790 | 1,825 | 0 |
| 31 Mar 23 | 9,603 | 789 | 1,832 | 0 |
| 31 Dec 22 | 9,883 | 942 | 1,838 | 0 |
| 30 Sep 22 | 10,294 | 1,230 | 1,736 | 0 |
| 30 Jun 22 | 10,582 | 1,479 | 1,705 | 0 |
| 31 Mar 22 | 10,679 | 1,874 | 1,715 | 0 |
| 31 Dec 21 | 10,788 | 1,988 | 1,723 | 0 |
| 30 Sep 21 | 11,046 | 2,175 | 1,674 | 0 |
| 30 Jun 21 | 11,058 | 2,238 | 1,642 | 0 |
| 31 Mar 21 | 10,335 | 1,794 | 1,571 | 0 |
| 31 Dec 20 | 9,437 | 1,425 | 1,545 | 0 |
| 30 Sep 20 | 8,361 | 1,101 | 1,414 | 0 |
| 30 Jun 20 | 7,531 | 749 | 1,378 | 0 |
| 31 Mar 20 | 7,657 | 771 | 1,376 | 0 |
| 31 Dec 19 | 7,726 | 835 | 1,457 | 0 |
| 30 Sep 19 | 7,639 | 709 | 1,402 | 0 |
| 30 Jun 19 | 7,572 | 707 | 1,406 | 0 |
| 31 Mar 19 | 7,538 | 720 | 1,387 | 0 |
| 31 Dec 18 | 7,531 | 733 | 1,395 | 0 |
| 30 Sep 18 | 7,557 | 860 | 1,378 | 0 |
| 30 Jun 18 | 7,524 | 808 | 1,359 | 0 |
| 31 Mar 18 | 7,469 | 782 | 1,372 | 0 |
| 31 Dec 17 | 7,402 | 769 | 1,421 | 0 |
| 30 Sep 17 | 7,398 | 671 | 1,413 | 0 |
| 30 Jun 17 | 7,427 | 701 | 1,480 | 0 |
| 31 Mar 17 | 7,469 | 702 | 1,558 | 0 |
| 31 Dec 16 | 7,214 | 642 | 1,337 | 0 |
| 30 Sep 16 | 7,503 | 675 | 1,624 | 0 |
| 30 Jun 16 | 7,498 | 825 | 1,637 | 0 |
| 31 Mar 16 | 7,517 | 748 | 1,637 | 0 |
| 31 Dec 15 | 7,493 | 706 | 1,616 | 0 |
| 30 Sep 15 | 7,527 | 703 | 1,654 | 0 |
| 30 Jun 15 | 7,551 | 491 | 1,657 | 0 |
Kaliteli Kazançlar: DGX yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: DGX 'nin mevcut net kar marjları (9%) geçen yılın (8.8%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: DGX şirketinin kazançları son 5 yılda yılda 20.3% oranında azaldı.
Büyüme Hızlandırma: DGX 'un son bir yıldaki kazanç büyümesi ( 14.3% ) 5 yıllık ortalamasını (yıllık -20.3% ) aşıyor.
Kazançlar vs. Sektör: DGX geçen yılki kazanç büyümesi ( 14.3% ) Healthcare sektörünün 17.2% performansını geride bırakmadı.
Özkaynak Getirisi
Yüksek ROE: DGX 'nin Özsermaye Getirisi ( 13.9% ) düşük olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/01 21:08 |
| Gün Sonu Hisse Fiyatı | 2026/05/01 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Quest Diagnostics Incorporated 36 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |